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Objective To determine the incidence of acute kidney injury (AKI) in infants exposed to nephrotoxic drug combi-
nations admitted to 268 neonatal intensive care units managed by the Pediatrix Medical Group.
Study design We included infants born at 22-36 weeks gestational age, £120 days postnatal age, exposed to
nephrotoxic drug combinations, with serum creatinine measurements available, and discharged between 2007
and 2016. To identify risk factors associated with a serum creatinine definition of AKI based on the Kidney Disease:
Improving Global Outcomes criteria, we performed multivariable logistic and Cox regression adjusting for gesta-
tional age, sex, birth weight, postnatal age, race/ethnicity, sepsis, respiratory distress syndrome, baseline serum
creatinine, and duration of combination drug exposure. The adjusted odds of AKI were determined relative to
gentamicin + indomethacin for the following nephrotoxic drug combinations: chlorothiazide + ibuprofen;
chlorothiazide + indomethacin; furosemide + gentamicin; furosemide + ibuprofen; furosemide + tobramycin;
ibuprofen + spironolactone; and vancomycin + piperacillin-tazobactam.
Results Among 8286 included infants, 1384 (17%) experienced AKI. Onmultivariable analysis, sepsis, lower base-
line creatinine, and duration of combination therapy were associated with increased odds of AKI.
Furosemide + tobramycin and vancomycin + piperacillin-tazobactam were associated with a decreased risk of
AKI relative to gentamicin + indomethacin in both the multivariable and Cox regression models.
Conclusions In this cohort, infants receiving longer durations of nephrotoxic combination therapy had an
increased odds of developing AKI. (J Pediatr 2021;228:213-9).A
cute kidney injury (AKI) in critically ill infants is common and associated with poor outcomes and highmortality.1 The
Assessment of Worldwide Acute Kidney Epidemiology in Neonates study performed in critically ill neonates across 24
neonatal intensive care units (NICUs) reported a 30% incidence of AKI overall and 18%, 48%, and 37% for gestational
ages of 22-28 weeks, 29-35 weeks, and ³36 weeks, respectively. In the Assessment of Worldwide Acute Kidney Epidemiology in
Neonates study, infants with AKI had higher mortality (9.7% vs 1.4%; P < .001) and longer hospital stays compared with infantsFrom the 1Division of Pharmacotherapy and
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content is solely the responsibility of the authors andwithout AKI after adjusting for known risk factors.2 Infant risk factors that have
been associated with AKI from small single-site studies include very low birth
weight (VLBW), congenital heart disease, perinatal asphyxia, hypoxic ischemic
encephalopathy, sepsis, respiratory distress, and extracorporeal membrane
oxygenation.3-5
Besides these identified risk factors, nephrotoxic drugs are commonly adminis-
tered to infants and have also been associated with an increased risk of AKI among
critically ill infants.6-8 The most common nephrotoxic drugs administered to
infants in the NICU include gentamicin, vancomycin, furosemide, indomethacin,
tobramycin, acyclovir, chlorothiazide, spironolactone, piperacillin-tazobactam,
amphotericin B, and ibuprofen.9 A study in 1828 critically ill children, including
term infants ³2 weeks of age, reported an increased risk for AKI as the number
of nephrotoxic drugs increased (OR, 1.3; 95% CI, 1.2-1.4).8 Furthermore, in a
sample of 107 VLBW infants in the NICU, infants who experienced AKI received
more nephrotoxic drugs per day than those who did not experience AKI (0.24 vs
0.15; P = .003).7
A single-site study of 86 term newborns in the NICU reported that infants are
at high risk of AKI when treated with aminoglycosides in combination with di-
uretics for >4.5 days.10 Similarly, nonsteroidal anti-inflammatory drugsdoes not necessarily represent the official views of the
National Institutes of Health. R.G. has received support
from industry for research services (https://dcri.org/
about-us/conflict-of-interest/). The other authors declare
no conflicts of interest.
AKI Acute kidney injury
NICU Neonatal intensive care unit
VLBW Very low birth weight
Enter the top 50 drugs commonly administered to infants 
discharged from NICUs managed by the Pediatrix 
Medical Group1 into Micromedex
Filtered by drug combinations with good or excellent 
evidence for a nephrotoxic drug-drug interaction* 
Final drug combinations selected: 
• chlorothiazide plus ibuprofen
• chlorothiazide plus indomethacinincreased the risk of AKI in neonates receiving vancomycin
with and without gentamicin with an OR of 5.2
(P < .001).11 Furthermore, 10 preterm infants with patent
ductus arteriosus who received gentamicin + indomethacin
were reported to have significant elevations in gentamicin
concentrations and serum creatinine and decreases in 24-
hour urine output and fluid intake after coadministration
with indomethacin.12 The primary aim of this study was to
use a large multicenter database of infants to determine the
incidence of AKI and the relative nephrotoxicity of nephro-
toxic drug combinations likely encountered in the NICU.
Methods
We identified infants £120 days postnatal age (those hospital-
ized for longer times are likely to have other comorbidities),
born at 22-36 weeks gestational age, exposed to only 1 neph-
rotoxic drug combination, discharged from any of 268 NI-
CUs managed by the Pediatrix Medical Group between
2007 and 2016, and with serum creatinine values available
in the medical chart. The Pediatrix Medical Group maintains
electronic medical data prospectively captured through notes
generated by clinicians including: admission history and
physicals, daily progress notes, laboratory results, discharge
summaries, drugs, diagnoses, and maternal history and de-
mographics. We excluded infants that were predisposed to
AKI to decrease confounding of the association between
AKI and nephrotoxic drugs. The following exclusion criteria
were applied: infants with hypoxic ischemic encephalopathy,
those with underlying congenital renal dysfunction or dis-
ease, and those who received dialysis before receiving neph-
rotoxic drugs, or received extracorporeal membrane
oxygenation. The study was approved by the Duke University
Institutional Review Board with a waiver of informed
consent.• furosemide plus gentamicin
• furosemide plus ibuprofen
• furosemide plus tobramycin
• ibuprofen plus spironolactone
• vancomycin plus piperacillin-tazobactam
• gentamicin plus indomethacin
The primary endpoint was to determine the adjusted 
odds of AKI for each nephrotoxic drug combination 
while controlling for confounding variables 
Figure. Approach for determining drug combinations asso-
ciatedwith AKI risk in infants. *Excellent evidencewas defined
as the existence of controlled studies clearly establishing an
interaction. Good evidence was defined as the existence of
documentation strongly suggesting an interaction but lacking
well-controlled studies. 1Hsieh EM, Hornik CP, Clark RH,
Laughon MM, Benjamin DK Jr, Smith PB; Best Pharmaceu-
ticals for Children Act—Pediatric Trials Network. Medication
use in the neonatal intensive care unit. Am J Perinatol
2014;31:811-21.Definitions
The association between AKI and nephrotoxic drug exposure
was evaluated for the following drug combinations: chloro-
thiazide + ibuprofen; chlorothiazide + indomethacin; furose-
mide + gentamicin; furosemide + ibuprofen; furosemide +
tobramycin; ibuprofen + spironolactone; vancomycin +
piperacillin-tazobactam; and gentamicin + indomethacin.
These combinations were selected by entering into Microme-
dex the top 50 drugs commonly administered to infants dis-
charged from NICUs managed by the Pediatrix Medical
Group, and then filtering by those drug combinations based
on the classification system within Micromedex in which
there was good or excellent evidence for a nephrotoxic
drug-drug interaction in either adults or pediatric patients.9
Excellent evidence was defined by Micromedex as the
existence of controlled studies clearly establishing an
interaction. Good evidence was defined by Micromedex as
the existence of documentation strongly suggesting an
interaction but lacking well-controlled studies (Figure).
We excluded patients who received >1 of these drugcombinations during hospitalization. For infants receiving
multiple courses of the same drug combination, we
included serum creatinine data for the first course only.
Based on the Kidney Disease: Improving Global Outcomes
2012 guidelines, we defined AKI as an increase in serum
creatinine ³0.3 mg/dL or ³1.5 times the baseline creatinine,
which was considered to be the most recent serum creatinine
value within 2 days of first drug combination exposure.13 We
excluded all serum creatinine values of >10 mg/dL owing to
our concern that these values may have been entered in error.
Serum creatinine values during the first 3 postnatal days were
excluded because these levels are more reflective of maternal
serum creatinine values.14,15 We used a serum creatinine-
based AKI definition because the Pediatrix database did not
capture urine output. Drug combination exposure was
defined as the administration of both drugs to the same in-
fant on the same day. AKI was attributed to the nephrotoxic
drug combination if it occurred after the first day of exposure
through 6 days after last day of drug combination exposure.
Beyond 6 days, concentrations for all drugs evaluated were
considered to be negligible based on the passage of 5 half-lives
of the drugs.16 For example, the drug evaluated with the
longest half-life, furosemide, has an average half-life in neo-
nates ranging from 7.7 to 26.8 hours.17 Although we only
considered the first course of combination therapy, if the
same drug combination was stopped and resumed between
the first day and 6 days after the last day of drug exposure,
then this was counted as 1 course of drug combination expo-
sure. Demographic data included gestational age, sex, birth
weight, race, and postnatal age. Sepsis was defined as the
presence of any positive culture. Respiratory distress syn-
drome was defined as the exposure to surfactant in the first
7 postnatal days.Statistical Analyses
We used the c2 test to examine demographic differences be-
tween infants receiving nephrotoxic drug combinations who
experienced AKI and infants receiving nephrotoxic drug
combinations who did not experience AKI. Categorical vari-
ables were presented as count (percentages) and continuous
variables were presented as median (IQR). Gestational age
was stratified by <24, 24-26, 27-29, 30-32, and 33-36 weeks;
birth weight was stratified by £750, 751-1000, 1001-1500,
1501-2500, and >2500 g; and postnatal age was stratified by
<2, 2-3, 4-5, 6-7, and 8-16 weeks.
To estimate the association between nephrotoxic drug
combinations and AKI, we used both a logistic model with
random effects across sites and a Cox survival model with
shared frailty across sites, the latter allowing for multiple fail-
ures (new instances of AKI) for each patient. With the logistic
model, the outcome was AKI at any time under observation,
and drug exposure was the total number of days the patient
was treated with the drug combination. For the Cox model,
drug exposure relevant to each day was the number of the
prior 6 days on which the patient was treated with the drug
combination (thus allowing for nephrotoxic drug to clear
from the body, as previously described). Both models
controlled for gestational age, sex, birth weight, postnatal
age, race, sepsis, respiratory distress syndrome, and baseline
serum creatinine. Significance for all tests was set at
P < .05. Stata version 16.1 (StataCorp, College Station, Texas)
was used to perform the statistical analysis.Results
Clinical Characteristics
We identified 23 399 infants exposed to nephrotoxic drug
combinations who were admitted to the Pediatrix Medical
Group affiliated NICUs between 2007 and 2016. Of the 23
399 patients meeting inclusion criteria, 15 113 were excluded
because they did not have ³2 serum creatinine measurements
available, resulting in 8286 infants for analysis. We excluded
<1% of serum creatinine values >10 mg/dL owing to our
concern that these values may have been entered in error.
There were an average of 6 serum creatinine measurements
per infant in the group that experienced AKI and an averageof 5 serum creatinine measurements per infant in the group
that did not experience AKI. The overall incidence of AKI was
17% (1384/8286) in infants exposed to nephrotoxic drug
combinations (11% were diagnosed as stage 1, 4% were diag-
nosed as stage 2, and 2% were diagnosed as stage 3). The me-
dian birth weight was 920 g (IQR, 700-1400 g) in infants with
AKI and 945 g (IQR, 710-1395 g) in infants without AKI. The
median gestational age was 27 weeks (IQR, 25-31 weeks) in
infants with AKI and was 27 weeks (IQR, 25-30 weeks) in in-
fants without AKI. The median postnatal age at start of drug
combination was 10 weeks (IQR, 5-25 weeks) for infants with
AKI and 11 weeks (IQR, 5-26 weeks) for infants without AKI.
The median duration of combination therapy was 3 days
(IQR, 1-6 days) for infants with AKI and was 2 days (IQR,
1-5 days) for infants without AKI. Infant demographics
that differed between infants who experienced AKI and
who did not experience AKI included postnatal age, race,
sepsis, and length of combination therapy (Table I).
Risk Factors for AKI
In the logistic model, sepsis, lower baseline creatinine, and
longer duration of combination therapy were associated
with an increased risk of AKI (Table II). There were no
differences between infants with and without AKI across
birth weight, postnatal or gestational age groups, sex, race,
or respiratory distress syndrome status (Table II). In the
Cox model, longer duration of combination therapy was
associated with increased risk of AKI, as were birth weight
<1000 g, postnatal age <2 weeks, Hispanic race, lower
baseline creatinine, and sepsis. Gestational age between 27
and 29 weeks and respiratory distress syndrome were
associated with a decreased risk of AKI (Table III).
Nephrotoxic Drug Combinations Associated with
AKI
No infants received chlorothiazide + ibuprofen or ibuprofen +
spironolactone. The prevalence of AKI was 316 of 1788 (18%)
for gentamicin+ indomethacin, 2 of 6 (33%) for chlorothiazide
+ indomethacin, 697 of 4265 (16%) for furosemide + genta-
micin, 3 of 25 (12%) for furosemide + ibuprofen, 94 of 636
(15%) for furosemide + tobramycin, and 272 of 1566 (17%)
for vancomycin + piperacillin-tazobactam. The median post-
natal age for the initiation of nephrotoxic drug combinations
was 23 days (IQR, 22-46) for chlorothiazide + indomethacin;
9 days (IQR, 2-29 days) for furosemide + gentamicin; 12
days (IQR, 6-18 days) for furosemide + ibuprofen; 28 days
(IQR, 16-47 days) for furosemide + tobramycin; 1 day (IQR,
0-3 days) for gentamicin + indomethacin; and 15 days (IQR,
8-29 days) for vancomycin + piperacillin-tazobactam.
Furosemide + tobramycin and vancomycin + piperacillin-
tazobactam were associated with a decreased risk of AKI in
both the logistic model and the Cox model, relative to the
reference group (gentamicin + indomethacin) (Table II and
Table III). Chlorothiazide + indomethacin was associated
with an increased risk of AKI relative to gentamicin +
indomethacin in the Cox (but not logistic) model, but the
sparse usage of chlorothiazide + indomethacin (n = 6)
Table I. Demographics and clinical characteristics of





(n = 1384 [17%])
Did not experience AKI





3 (1-6) 2 (1-5) <.01
Birth weight (g) .07
£750 438 (32) 2017 (29)
751-1000 340 (25) 1698 (25)
1001-1500 287 (21) 1663 (24)
1501-2500 226 (16) 1100 (16)
>2500 93 (7) 424 (6)
Gestational age (weeks) .20
<24 97 (7) 433 (6)
24-26 506 (37) 2478 (36)
27-29 360 (26) 1917 (28)
30-32 180 (13) 991 (14)
33-36 241 (17) 1083 (16)
Postnatal age (weeks) .01
< 2 850 (62) 3977 (58)
2-3 248 (18) 1441 (21)
4-5 122 (9) 742 (11)
6-7 71 (5) 349 (5)
8-16 85 (6) 376 (5)
Male sex 789 (57) 3927 (57) .92
Race/ethnicity .01
White 523 (39) 2735 (41)
Black 306 (23) 1631 (25)
Hispanic 448 (34) 1938 (29)
Other 57 (4) 344 (5)
Sepsis 805 (58) 3753 (54) .01
Respiratory distress
syndrome
995 (72) 4948 (72) .88
c2 tests were used to examine demographic differences between infants receiving nephrotoxic
drug combinations who experienced AKI and infants receiving nephrotoxic drug combinations
who did not experience AKI. For some of the covariates, there were missing data recorded in the
database (25 for postnatal age, 304 for race/ethnicity, and 8 for sex). Categorical variables
were presented as count (column percentages) relative to the total number of subjects with
and without AKI, respectively. Significance was established at a P value of <.05.
Table II. Random effects logistic model of AKI among
infants born at 22-36 weeks gestation between 2007 and
2016
Categories AKI OR (95% CI) P value
Nephrotoxic drug combination
Chlorothiazide + indomethacin 2.95 (0.50-17.5) .23
Furosemide + gentamicin 0.94 (0.79-1.13) .51
Furosemide + ibuprofen 0.76 (0.22-2.64) .67




Gentamicin + indomethacin Reference
Duration of therapy (days) 1.04 (1.02-1.06) <.01
Baseline creatinine 0.62 (0.50-0.78) <.01
Birth weight (g)
£750 1.35 (0.86-2.13) .19
751-1000 1.20 (0.78-1.86) .40
1001-1500 1.02 (0.69-1.52) .92
1501-2500 1.01 (0.75-1.37) .93
>2500 Reference
Gestational age (weeks)
<24 0.92 (0.58-1.46) .72
24-26 0.85 (0.58-1.26) .42
27-29 0.86 (0.60-1.21) .38
30-32 0.86 (0.65-1.15) .31
33-36 Reference
Postnatal age (weeks)
<2 1.33 (0.98-1.80) .07
2-3 0.98 (0.73-1.33) .91
4-5 0.81 (0.58-1.12) .20
6-7 1.05 (0.72-1.51) .81
8-16 Reference
Male 1.03 (0.91-1.17) .62
Race/ethnicity
Black 0.92 (0.78-1.10) .37
Hispanic 1.11 (0.94-1.31) .23
Other 0.82 (0.60-1.12) .22
White Reference
Sepsis 1.25 (1.09-1.44) <.01
Respiratory distress syndrome 0.96 (0.82-1.12) .59
Multivariable logistic regression was performed to determine the association between AKI and
nephrotoxic drug combinations (relative to the arbitrarily chosen reference group,
gentamicin + indomethacin) adjusting for the following confounding variables: gestational
age, sex, birth weight, postnatal age, race, sepsis, respiratory distress syndrome, and duration
of combination drug exposure. Random effects by site were assumed, to control for differences
across sites. Of the 8286 infants meeting inclusion criteria, 7913 were included in this regres-
sion analysis because Stata SE excludes subjects missing values for any of these covariates.
Baseline creatinine was defined as the most recent serum creatinine value within 2 days of first
drug combination exposure. Significance was established at P < .05. None of the infants
received chlorothiazide + ibuprofen or ibuprofen + spironolactone.makes us reluctant to put much weight on this finding (Table
III).
Discussion
Although nephrotoxic drug exposure has been associated
with AKI in VLBW infants and critically ill term infants ³2
weeks of age, this multicenter study investigated AKI after
exposure to combinations of nephrotoxic drugs in infants
in the NICU of varying gestational ages and birth weights.6-
8 We found that infants receiving longer nephrotoxic combi-
nation therapy were more likely to develop AKI. A study of
VLBW infants also reported that infants who experienced
AKI had greater total nephrotoxic drug days than infants
who did not experience AKI (23.9 days vs 9.9 days;
P < .0001).7 Similarly, in hospitalized noncritically ill patients
aged 1 day to 18 years of age, patients with AKI were exposed
to more nephrotoxic drugs. In the Assessment of Worldwide
Acute Kidney Epidemiology in Neonates study, the incidence
of AKI was highest in the oldest (>36 weeks) and youngest
(³22 to <29 weeks) gestational age groups.2 It is likely that
younger gestational age is associated with AKI, but in our
sample, only the 27-29 week group with the Cox modelreached statistical significance for a lower risk of AKI relative
to the 33-35 week group. Similar to previous studies in in-
fants, sepsis was positively associated with AKI in this cohort
of infants.4,18-20 A postnatal age of <2 weeks was associated
with AKI in the Cox model estimates. Infants are particularly
susceptible to AKI soon after birth as the postnatal kidney
adapts to the extrauterine environment. The glomerular
filtration rate increases from about 5 to 40 mL/min/
1.73 m2 during the first week of life owing to increasing cen-
tral to peripheral renal blood flow and decreasing renal
vascular resistance.1 Thus, glomeruli, which reside in the
more peripheral renal cortex, are particularly more suscepti-
ble to insult as a result. In addition, a birth weight of <1000 g
was associated in the Coxmodel with an increased risk of AKI
relative to infants >2500 g. A study in VLBW infants reported
that there was an inverse linear relationship between birth
Table III. Shared frailty Cox proportional hazards
model of AKI in preterm infants (born at 22-37 weeks
of gestation) between 2007 and 2016
Category
Hazard Ratio
(HR) (95% CI) P value
Nephrotoxic drug combination
Chlorothiazide + indomethacin 2.73 (1.04-7.16)
Furosemide + gentamicin 1.01 (0.90-1.13)
Furosemide + ibuprofen 0.44 (0.14-1.37)




Gentamicin + indomethacin Reference
Duration of therapy (days) 1.06 (1.02-1.10) <.01
Baseline creatinine 0.54 (0.46-0.62) <.01
Birth weight (g)
£750 1.60 (1.20-2.11) <.01






















Sepsis 1.13 (1.04-1.23) <.01
Respiratory distress syndrome 0.89 (0.81-0.98)
A Cox proportional hazards model was estimated to determine the association between AKI and
nephrotoxic drug combinations (relative to the arbitrarily chosen reference group,
gentamicin + indomethacin) adjusting for the time-dependent variable (duration of combination
therapy) and other fixed covariates (gestational age, sex, birth weight, postnatal age, race,
sepsis, and respiratory distress syndrome). Shared frailty within sites was assumed to control
for site specific effects. Significance was established at P < .05. Baseline creatinine was
defined as the most recent serum creatinine value within 2 days of first drug combination expo-
sure. None of the infants received chlorothiazide + ibuprofen or ibuprofen + spironolactone.weight and nephrotoxic drugs received per day which
increased their risk of AKI.7 A lower baseline serum creati-
nine was associated with an increased risk of AKI, which is
likely because preterm neonates can have low serum creati-
nine levels and small increases can lead to a classification of
AKI using our serum creatinine based AKI definition.
The overall incidence of AKI in this cohort of infants
exposed to nephrotoxic drug combinations was 17%. The
incidence of AKI in infants is highly variable depending on
the definition of AKI used, the population studied, and the
number of study sites, infants, and serum creatinine mea-
surements available.1,2,21,22 For example, a single-site study
of 312 infants reported that 24% of infants developed AKI
based on a decrease in the glomerular filtration rate of
³25% from baseline or a decrease in urine output of
<1.5 mL/kg/hour for 24 hours.23 Another single-site study
of 1992 neonates reported an AKI prevalence of 8.4% basedon an increase in the serum creatinine of >1.5 mg/dL for
> 24 hours or that increased at the rate of 0.3 mg/dL/day after
the first 48 hours of birth.24 Moreover, a recently published
multicenter cohort study in 2022 infants identified a 30%
incidence of AKI using the following AKI definition: serum
creatinine increase of ³0.3 mg/dL or ³50% higher than pre-
vious lowest value, or if urine output was <1 mL/kg/hour
on postnatal days 2-7.2
Furosemide + tobramycin and vancomycin + piperacillin-
tazobactam were associated with a decreased risk of AKI
relative to gentamicin + indomethacin. A study of 10 preterm
infants with patent ductus arteriosus who received
gentamicin + indomethacin reported a significant elevation
in gentamicin peak and trough concentrations and a slight
but significant increase in serum creatinine before and after
coadministration with indomethacin.12 Indomethacin can
decrease glomerular filtration by inhibiting renal prosta-
glandin production, which may result in decreased clearance
of gentamicin, leading to gentamicin accumulation and
nephrotoxicity.12,25,26 Several studies have reported that to-
bramycin is less nephrotoxic than gentamicin in adult pa-
tients. Tobramycin was significantly less nephrotoxic than
gentamicin in a study performed in 201 critically ill older
adults (37% vs 22%; P < .02) using a serum creatinine defi-
nition of AKI.27 Additionally, a prospective, randomized,
double-blind trial in 258 adult patients with suspected sepsis
treated with tobramycin or gentamicin also reported that
nephrotoxicity occurred less frequently with tobramycin
than gentamicin (26% vs 12%; P < .025).28 Another prospec-
tive study in 62 adult patients reported that gentamicin was
associated with renal failure more than three times more
often than tobramycin.29 Several studies have suggested
that nephrotoxicity for vancomycin administered alone or
in combination with gentamicin in premature infants and
pediatric patients is extremely rare.30-32 However, a retro-
spective study in pediatric patients (median, 0.22 years;
IQR, 0-6.3 years) receiving piperacillin-tazobactam + vanco-
mycin reported a 2.5 increased relative risk (P = .03)
compared with pediatric patients receiving cefepime + van-
comycin.33 Likewise, a multicenter study reported that
vancomycin + piperacillin/tazobactam was associated with
AKI in children (6 months-18 years of age) during the first
week of hospitalization compared with children receiving
vancomycin + a similar spectrum b-lactam agent.34 It is chal-
lenging to directly compare our results with other studies in
pediatric patients because there are few studies investigating
AKI risks for nephrotoxic drug combinations in infants, and
no studies in adults or infants have directly compared neph-
rotoxicity for all of these drug combinations simultaneously.
There were no infants in our analysis who received chloro-
thiazide or spironolactone in combination with ibuprofen.
Ibuprofen is most commonly administered to premature in-
fants in the first few weeks after birth for the indication of pat-
ent ductus arteriosus.35 In contrast, infants may be more likely
to receive diuretic therapy with chlorothiazide or spironolac-
tone later in the hospital course to treat pulmonary sequelae
of developing or established bronchopulmonary dysplasia.
There may also be no infants receiving chlorothiazide + spiro-
nolactone or chlorothiazide + ibuprofen because we only
considered the first course of combination therapy. Therefore,
infantsmayhavebeen excluded if they received other combina-
tion therapy, such as gentamicin + indomethacin or furose-
mide + gentamicin, before receiving these drug combinations.
As a retrospective study, our analysis was limited to medical
and laboratory data reported in the medical chart, so we were
unable to evaluate urine output or glomerular filtration rate.
We excluded infants if they did not have ³2 serum creatinine
values (n = 15 113) because we did not have sufficient data
to conclude whether they experienced AKI during hospitaliza-
tion. For stage 1 of the Kidney Disease: Improving Global Out-
comes 2012 guidelines, the increase in serum creatinine values
should be within 7 days of each another, however, we assessed
the increase in serum creatinine during the exposure duration
of nephrotoxic drug.13 This factor may slightly increase the as-
sociation between AKI and nephrotoxic drugs, but should not
affect the relative nephrotoxicity among drug combinations.
Furthermore, our systematic approachof selectingnephrotoxic
drug combinations was based upon the availability of good or
excellent evidence for a nephrotoxic drug-drug interaction us-
ing Micromedex. Therefore, not every nephrotoxic drug com-
bination encountered in the NICU was evaluated. We also did
not account for drug dose or concentrations, but we did find
that duration of drug combination therapy was associated
with an increased risk of AKI. Future studies could be per-
formed evaluating the association between dosing and nephro-
toxic combination drug exposure with AKI in infants. In the
Cox regression model, chlorothiazide + indomethacin was
associated with an increased risk of AKI relative to gentamicin
+ indomethacin, but these findings may not be accurate given
that there were only 6 infants receiving chlorothiazide + indo-
methacin.Wealso recognize that an assessment ofAKI risks for
nephrotoxic drug combinations relative to monotherapy of
nephrotoxic drugs may be a more clinically useful analysis;
however, we do not present such an analysis because of the
inherent sampling bias in our dataset. Owing to clinician con-
cerns for AKI in infants receiving nephrotoxic drug combina-
tions, serum creatinine values were more frequently obtained
in infants receiving nephrotoxic drug combinations. In
contrast, serum creatinine values were likely only obtained in
infants receiving monotherapy when there was a clinical suspi-
cion of AKI. Thus, the incidence of AKI among infants
receiving monotherapy was biased upward relative to infants
receiving drug combinations (data not shown).
In this cohort of infants exposed to nephrotoxic drug com-
binations, the overall incidence of AKI was 17%. Furosemide
+ tobramycin and vancomycin + piperacillin-tazobactam
were associated with a decreased risk of AKI relative to genta-
micin + indomethacin. The duration of combination therapy
was associated with an increased risk of AKI regardless of the
nephrotoxic drug administered. Therefore, administering
combinations of nephrotoxic drugs for the shortest time
possible or switching to a less nephrotoxic alternative agent
may decrease the risk of AKI in infants. nSubmitted for publication Mar 19, 2020; last revision received Aug 6, 2020;
accepted Aug 13, 2020.
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